Novo Holdings
Novo Holdings, established in 1999, is a Danish asset management firm based in Copenhagen. It serves as the investment arm of the Novo Nordisk Foundation, managing its assets and wealth. The company's primary focus is the life science sector, with a diversified portfolio comprising equities, bonds, real estate, infrastructure, and private investments. Novo Holdings maintains a significant influence on Novo Nordisk A/S and Novozymes A/S, ensuring these companies align with the Novo Group's visions and values. It also invests in early and growth-stage life science companies through its venture capital arm, Novo Ventures, which targets investments ranging from USD 5 million to USD 30 million.
Anna Fan
Senior Partner, Life Sciences Operating Committee, Venture Investments, Venture Investments (US) Inc
Past deals in Ireland
Fire1
Venture Round in 2025
Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.
Fire1
Venture Round in 2023
Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.
Alder Biopharmaceuticals
Series D in 2012
Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Bothell, Washington, focused on discovering, developing, and commercializing therapeutic antibodies. The company aims to transform treatment paradigms for patients with migraine and other conditions, utilizing proprietary technologies to enhance the efficacy and durability of therapeutic responses. Its lead product candidate, eptinezumab, is a monoclonal antibody designed to prevent migraines, currently in late-stage clinical development. Additionally, Alder is developing ALD1910, a preclinical monoclonal antibody for migraine prevention, and Clazakizumab, which targets interleukin-6 and has completed two Phase 2b clinical trials. Alder also collaborates with CSL Limited to develop Clazakizumab for preventing solid organ transplant rejection. The company operates primarily in the United States, Australia, and Ireland, where it seeks to address unmet medical needs in various therapeutic areas, including cancer, autoimmune diseases, and inflammatory disorders. Founded in 2002, Alder BioPharmaceuticals operates as a subsidiary of H. Lundbeck A/S.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.